The FDA has approved Basilea Pharmaceutica’s advanced generation cephalosporin antibiotic, Zevtera (ceftobiprole medocaril), for the treatment of three major indications: Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). As the first drug to reach the US market for the treatment of SAB in over 15 years, Zevtera will play a unique and critical role in the future management of this serious, and commonly fatal infection, says GlobalData.
FDA Approves New Antibiotic for Three Different Uses
Basilea launches new cephalosporin antibiotic in the UK